On May 14, 2019 the INTEGRIS Advanced Cardiac Care team celebrated the 100th implant of the HeartMate 3 blood pump, bringing the total number of LVADS implanted at INTEGRIS Health to more than 500.
INTEGRIS Health is a national leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts. In fact, in 2014, INTEGRIS Health was the first in the country to implant the HeartMate 3 out of 69 centers eventually involved.
INTEGRIS Health partnered with Duke, Mayo, Columbia-Presbyterian, Cleveland Clinic and others to launch the HM3 clinical trial. “Not only was it the biggest, fastest enrolling trial in this field, but it was the most important trial to date proving the efficacy of LVAD therapy in the treatment of heart failure,” says James Long, M.D., the Director of the Nazih Zuhdi Transplant Institute and INTEGRIS Advanced Cardiac Care.
As a result of the trial, the HeartMate 3 pump is now the new evidence-based standard in LVAD therapy with high success rates and lower
INTEGRIS Advanced Cardiac Care is the only program in the state that offers all of these advanced therapies: left ventricular assist devices (LVAD), extracorporeal membrane oxygenation (ECMO), and heart transplant.
